Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
Mirum Pharmaceuticals is set to reveal the results of its Phase 3 clinical study on Monday at 8:30 a.m. ET. The study, known as EXPAND, evaluates the effectiveness of LIVMARLI, a drug for treating pruritus in patients with rare liver diseases. To join the investor call, U.S. participants can dial +1 833 461 5787 while international callers should use +1 585 542 9983 with access code 486697901.
The results will also be available on the company's website and can be accessed through a webcast. LIVMARLI is currently approved for treating Alagille syndrome and progressive familial intrahepatic cholestasis, but the study aims to expand its use for cholestatic pruritus in children with ultra-rare liver diseases. In addition to LIVMARLI, Mirum Pharmaceuticals' commercial portfolio includes ATEBRIOZ for fibrodysplasia ossificans progressiva, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis.
The company's clinical-stage pipeline also includes drugs for primary sclerosing cholangitis, primary biliary cholangitis, chronic hepatitis delta virus, and Fragile X syndrome.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Mirum Pharmaceuticals to report Livmarli trial results Monday seekingalpha.com
